Smith & Nephew plc (LON:SN) Receives Consensus Recommendation of “Hold” from Analysts

Smith & Nephew plc (LON:SN) has earned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is GBX 1,381.33.

Several research analysts have recently commented on the company. Panmure Gordon reiterated a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a report on Tuesday, December 9th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,350 price objective on shares of Smith & Nephew in a research report on Tuesday, March 17th. Finally, Berenberg Bank reiterated a “hold” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a report on Friday, January 23rd.

Smith & Nephew Stock Performance

LON SN opened at GBX 1,200.50 on Wednesday. The stock’s fifty day moving average is GBX 1,267.04 and its two-hundred day moving average is GBX 1,281.84. The firm has a market capitalization of £13.16 billion, a price-to-earnings ratio of 43.22, a P/E/G ratio of 0.46 and a beta of 0.68. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.